Archive | September, 2017

RESI Boston 2017 Innovation Challenge – Winners Announced NYC Application is Now Open

28 Sep

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newOn Tuesday September 26th, RESI Boston was host to the largest RESI Innovation Challenge yet, with 40 companies competing for the “investment” votes of their fellow attendees. These innovative startups came from across the life science spectrum – develop ing novel products in biotech, medtech, diagnostics and healthcare IT, with the aim of addressing a wide range of different diseases. We hope that all will succeed in bringing their products to patients, but there could only be 3 prize winners. Without further ado, LSN would like to present the top three competitors:

First Place: Wellesley Pharmaceuticals

Nocturia, the frequent need to urinate at night, afflicts 2.3B people, causing insomnia, fatigue, depression, and lower quality of life. It leads to higher rates of heart disease, stroke, brain damage, and deadly falls, killing thousands daily. Wellesley’s Phase 2 trial ended 9/8/17. Results will be unblinded 10/2, but 50% of patients reported >25% nocturia reduction and 27% reported 40-96% benefits, with no side effects. 25% took placebo and 25% reported results averaging 0%. OAB drugs offer 10-15% benefits, bad side effects, and sell $2B/year! Licensing dozens of worldwide patents to big pharma comes next. We expect $10M upfront and 15% of revenue, while they take over all future costs, before launching our drug worldwide. Net margins should approach 95%.

Michael Quigley, VP of Investor Research, Life Science Nation | David Dill, CEO, Wellesley Pharmaceuticals | Dennis Ford, CEO, Life Science Nation

Second Place: Molecular Targeting Technologies

Molecular Targeting Technologies, Inc.’s (MTTI) TDURA is an imaging agent with a unique mechanism to “see” cell death. It is fast, sensitive and enables actionable tracking of cell damage, reducing toxicity,improving survival and minimizing healthcare costs. MTTI has demonstrated proof of efficacy in cardiotoxicity and oncology models. TDURA detected chemotherapy related cardiac dysfunction prior to existing technologies, detected tumor response to therapy as early as 1 day and distinguished responders from non-responders. TDURA is ready for clinical development. Phase II approval for the first indication is projected in 2022. Exit prior to phase III should deliver ≥$100 million value. MTTI has an experienced team, a strong IP and an innovative platform with multiple indications targeted to several unmet medical needs.

Michael Quigley, VP of Investor Research, Life Science Nation | Koon Yan “Chris” Pak, Co-Founder & CEO, Molecular Targeting Technologies, Inc. | Michael Silvon, Senior Vice President of Business Development, Molecular Targeting Technologies, Inc. | Dennis Ford, CEO, Life Science Nation

Third Place: RPS Diagnostics

RPS DIAGNOSTICS is developing FebriDx® for launch outside the USA in 2018. FebriDx is the first and only rapid, in-office test that uses a fingerstick blood sample to help differentiate viral from bacterial acute febrile respiratory infection. The FebriDx® test can be used to help triage infectious patients at the point of care, providing clinicians with a clear path to diagnosis and treatment, leading to more efficacious healthcare decisions. Test results are available in 15 minutes, allowing for an effective treatment plan to be established during the patient’s initial office visit.

Michael Quigley, VP of Investor Research, Life Science Nation | Dennis Ford, CEO, Life Science Nation | Doug Lawrence, CEO, RPS Diagnostics

Thank you to all who competed in the RESI Boston Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Apply for RESI NYC Innovation Challenge Now!

Just Released: Redefining Early Stage Investments (RESI) Conference Program Guide See What Global Life Science Investors Are Up To

21 Sep

By Nono Hu, Director of Marketing, LSN

It’s 5 days to go until RESI Boston, and LSN would like to present the RESI Program Guide. If you’d like to check out RESI Boston’s full lineup of speakers, sponsors, exhibitors, and innovators, you can read the program guide online now. With nineteen panel discussions, five entrepreneur workshops, dozens of vendors and the largest RESI Innovation Challenge ever, RESI will offer an overwhelming amount of content for early stage life science startups and the investors and strategic partners that want to meet them. You can check out the details below.

Click here to register RESI Boston 2017

Hot Investor Mandate 19: Canada VC Invests in Biotech, Medtech and Green Technology

21 Sep

A venture capital firm based in Canada provides equity capital to portfolio companies and is very flexible in the size of investments it makes, placing a high emphasis on innovation of potential portfolio companies. The firm is currently investing in Canadian companies only, with no set limit on the amount of funds or number of investments.

The firm is looking to invest primarily in innovative green technology as well as biotech therapeutics and medical technology, and is also open to looking at companies in diagnostics and healthcare IT. The firm will consider products of any stage of development, from pre-clinical to phase III as long as the company’s product displays high potential to positively impact the environment or healthcare. In addition, the firm is agnostic to indication and will look at anything that fits in the environment or healthcare sectors.

The firm has taken a board seat in its portfolio companies before, but this is not required by the firm. The companies do not need to have an experienced management team, as innovation is the most important factor that the firm expects from companies. The firm prefers to act as the lead investor, but is open to co-investing with other firms that share the firm’s interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 18: Family Office Invests Early in Novel Therapeutics, Devices and Life Science Tools

21 Sep

A family office based in California invests in primarily early-stage (seed, Series A) companies with truly innovative technologies with a typical investment size of $2-5M per company and can invest as low as $500K. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is seeking innovative technology that is outside traditional biotech. The company is agnostic across life science sectors, including therapeutics, devices, and tools, but will not look at Healthcare IT or digital health technologies. They are interested in therapeutics targeting novel first-in-class targets, and not in biosimilars or repurposed drugs. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 17: Hospital Network Fund Invests in Innovative Medical Technologies

21 Sep

A $150 million venture capital fund managed on behalf of a not-for-profit health system makes direct investments in innovative healthcare companies. Typical equity allocations range from $5-8 million over the life of a company. The firm typically co-invests with other VC funds but is also open to leading in a financing round. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market.

The firm is looking for innovative medical technologies that are in line with the organization’s mission, improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology.

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 16: Global VC Invests Early in Novel Biotech and Medical Device Platforms

21 Sep

A venture capital firm with offices across the US, Europe and Asia is currently looking to make new investments into biopharmaceutical and medical device companies from its two funds. The firm looks to invest in early stage companies and can provide up to about $17 million to a company over the lifetime of the investment. The firm is most interested in companies based in the US, Canada, Ireland, Singapore and will also consider exceptional opportunities elsewhere in Europe and in Asia. The firm plans to make approximately 8 new investments over the next 6-9 months.

The firm is interested in companies developing either biopharmaceuticals or medical devices. For biopharmaceuticals, the firm is interested in all modalities including small molecules, biologics, and cell and gene therapies. The firm is primarily interested in platform companies with the potential for multiple assets and strongly prefers technologies to be 1st in class or best in class, often originating from breakthrough chemistry or biology discoveries. The firm is looking for companies with assets in discovery through Phase 1 clinical trials. For medical devices, the firm is primarily interested in companies working on devices that have the ability to treat drug-like markets, as well as devices for self-pay markets. The firm is indication-agnostic in both biopharmaceuticals and devices.

The firm can both lead and co-lead investments, with a preference for taking a board seat. The firm prefers working with management teams with positive track records; however, they are open to working with incomplete or non-permanent management teams as well, especially for very early stage opportunities. The investment team has extensive operating experience and deep networks, which they can leverage to support companies as needed.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 15: Asset Management Group Invests in Medical Devices and Imaging

21 Sep

An asset management group based in China operates a USD fund of $50 million that invests in healthcare and technology startups. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, and healthcare IT products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that have completed a prototype and obtained FDA clearance or are ready for FDA submission. The firm is agnostic to indication areas.

The firm is looking for experienced management teams. The firm can leverage its innovation center to assist with commercialization in the China market. The firm my request distribution rights and board representation post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email